Interpretation of the RBANS in inpatient psychiatry: Clinical normative data and prevalence of low scores for patients with schizophrenia

Applied Neuropsychology

Volumn 16, Issue 1, 2009, Pages 31-41

  Iverson, Grant L ^a,b   Brooks, Brian L ^b   Haley, Glenn M T ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BC Mental Health & Addiction Services   (Canada)

Author keywords

Cognition; Neuropsychological screening; Normative data; RBANS; Schizophrenia

Indexed keywords

ADULT; AGED; ATTENTION; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; INPATIENTS; LANGUAGE; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 60549112577     PISSN: 09084282     EISSN: 15324826     Source Type: Journal    
DOI: 10.1080/09084280802644128     Document Type: Article

References (53)

1. Addington, J., & Addington, D. (2000). Neurocognitive and social functioning in schizophrenia: A 2.5 year follow-up study. Schizophrenia Research, 44(1), 47-56.
2. Addington, J., Brooks, B. L., & Addington, D. (2003). Cognitive functioning in first episode psychosis: Initial presentation. Schizophrenia Research, 62(1-2), 59-64.
3. Alptekin, K., Akvardar, Y., Kivircik Akdede, B. B., Dumlu, K., Isik, D., Pirincci, F., Yahssin, S., & Kitis, A. (2005). Is quality of life associated with cognitive impairment in schizophrenia? Progress in Neuro- Psychopharmacology & Biological Psychiatry, 29(2), 239-244.
4. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: American Psychiatric Association.
5. Beatty, W. W., Ryder, K. A., Gontkovsky, S. T., Scott, J. G., McSwan, K. L., & Bharucha, K. J. (2003). Analyzing the subcortical dementia syndrome of Parkinson's disease using the RBANS. Archives of Clinical Neuropsychology, 18(5), 509-520.
6. Bilder, R. M. (1997). Neurocognitive impairment in schizophrenia and how it affects treatment options. Canadian Journal of Psychiatry, 42(3), 255-264.
7. Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J. P., Citrome, L., McEvoy, J., Kunz, M., Chakos, M., Coopa, T. B., Horowitz, T. L., & Lieberman, J. A. (2002). Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 159(6), 1018-1028.
8. Dickerson, F., Boronow, J. J., Stallings, C., Origoni, A. E., Cole, S. K., & Yolken, R. H. (2004). Cognitive functioning in schizophrenia and bipolar disorder: Comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status. Psychiatry Research, 129(1), 45-53.
9. Duff, K., Patton, D., Schoenberg, M. R., Mold, J., Scott, J. G., & Adams, R. L. (2003). Age- and education-corrected independent normative data for the RBANS in a community dwelling elderly sample. The Clinical Neuropsychologist, 17(3), 351-366.
10. Duff, K., Schoenberg, M. R., Patton, D., Mold, J., Scott, J. G., & Adams, R. L. (2004). Predicting change with the RBANS in a community dwelling elderly sample. Journal of the International Neuropsychological Society, 10(6), 828-834.
11. Duff, K., Schoenberg, M. R., Patton, D., Paulsen, J. S., Bayless, J. D., Mold, J., Scott, J. E., & Adams, R. L. (2005). Regression-based formulas for predicting change in RBANS subtests with older adults. Archives of Clinical Neuropsychology, 20(3), 281-290.
12. Duff, K., Schoenberg, M. R., Patton, D. E., Mold, J. W., Scott, J. G., & Adams, R. L. (2008). Predicting cognitive change across 3 years in community-dwelling elders. The Clinical Neuropsychologist, 22(4), 651-661.
13. Evans, J. D., Heaton, R. K., Paulsen, J. S., McAdams, L. A., Heaton, S. C., & Jeste, D. V. (1999). Schizoaffective disorder: A form of schizophrenia or affective disorder? Journal of Clinical Psychiatry, 60(12), 874-882.
14. Freilich, B. M., & Hyer, L. A. (2007). Relation of the repeatable battery for assessment of neuropsychological status to measures of daily functioning in dementia. Psychological Reports, 101(1), 119-129.
15. Gold, J. M., Queern, C., Iannone, V. N., & Buchanan, R. W. (1999). Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: Sensitivity, reliability, and validity. American Journal of Psychiatry, 156(12), 1944-1950.
16. Gontkovsky, S. T., Mold, J. W., & Beatty, W. W. (2002). Age and educational influences on RBANS index scores in a nondemented geriatric sample. The Clinical Neuropsychologist, 16(3), 258-263.
17. Good, K. P., Kiss, I., Buiteman, C., Woodley, H., Rui, Q., Whitehorn, D., & Kopala, L. (2002). Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: An interim analysis. British Journal of Psychiatry Supplement, 43, s45-49.
18. Green, M. F., & Braff, D. L. (2001). Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biological Psychiatry, 49(4), 374-384.
19. Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000). Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? Schizophrenia Bulletin, 26(1), 119-136.
20. Green, M. F., Marder, S. R., Glynn, S. M., McGurk, S. R., Wirshing, W. C., Wirshing, D. A., Lieberman, R. P., & Mintz, J. (2002). The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone. Biological Psychiatry, 51(12), 972-978.
21. Gruber, O., Gruber, E., & Falkai, P. (2006). Articulatory rehearsal in verbal working memory: A possible neurocognitive endophenotype that differentiates between schizophrenia and schizoaffective disorder. Neuroscience Letters, 405(1-2), 24-28.
22. Heinrichs, R. W., Ammari, N., McDermid Vaz, S., & Miles, A. A. (2008). Are schizophrenia and schizoaffective disorder neuropsychologically distinguishable? Schizophrenia Research, 99(1-3), 149-154.
23. Hobart, M. P., Goldberg, R., Bartko, J. J., & Gold, J. M. (1999). Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, II: Convergent/discriminant validity and diagnostic group comparisons. American Journal of Psychiatry, 156(12), 1951-1957.
24. Holzer, L., Chinet, L., Jaugey, L., Plancherel, B., Sofia, C., Halfon, O., & Randolph, C. (2007). Detection of cognitive impairment with the repeatable battery for the assessment of neuropsychological status (RBANS) in adolescents with psychotic symptomatology. Schizophrenia Research, 95(1-3), 48-53.
25. Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261-276.
26. Keefe, R. S., Goldberg, T. E., Harvey, P. D., Gold, J. M., Poe, M. P., & Coughenour, L., Rock, S. L., Woolron, S., Tohen, M., Tollefron, G. D., Sanger, T. M., & Liberman, J. A. (2004). The brief assessment of cognition in schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research, 68(2-3), 283-297.
27. Keefe, R. S., Bilder, R. M., Harvey, P. D., Davis, S. M., Palmer, B. W., Gold, J. M., Meltzer, H. Y., Green, M. F., Miller, D. D., Canive, J. M., Adler, L. W., Manschreck, T. C., Swartz, M., Rosenheck, R., Perkins, D. O., Walker, T. M., Stoup, T. S., McEvoy, J. P., & Lieberman, J. A.. (2006a). Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology, 31(9), 2033-2046.
28. Keefe, R. S., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Rock, S. L., Woolson, S., Tohen, M., Tollefson, G. D., Sanger, T. M., & Lieberman, J. A. (2006b). Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biological Psychiatry, 59(2), 97-105.
29. Keefe, R. S., Young, C. A., Rock, S. L., Purdon, S. E., Gold, J. M., & Breier, A. (2006c). One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophrenia Research, 81(1), 1-15.
30. Kern, R. S., Nuechterlein, K. H., Green, M. F., Baade, L. E., Fenton, W. S., Gold, J. M., Keefe, R. S., Mesholam-Gately, R., Mintz, J., Seidman, L. J., Stover, E., & Marder, S. R. (2008). The MATRICS consensus cognitive battery, part 2: Co-norming and standardization. American Journal of Psychiatry, 165(2), 214-220.
31. Kim, S. W., Shin, I. S., Kim, J. M., Yang, S. J., Shin, H. Y., & Yoon, J. S. (2006). Association between attitude toward medication and neurocognitive function in schizophrenia. Clinical Neuropharmacology, 29(4), 197-205.
32. Kopelowicz, A., Liberman, R. P., Ventura, J., Zarate, R., & Mintz, J. (2005). Neurocognitive correlates of recovery from schizophrenia. Psychological Medicine, 35(8), 1165-1173.
33. Kurtz, M. M., Seltzer, J. C., Ferrand, J. L., & Wexler, B. E. (2005). Neurocognitive function in schizophrenia at a 10-year follow-up: A preliminary investigation. CNS Spectrums, 10(4), 277-280.
34. Larson, E., Kirschner, K., Bode, R., Heinemann, A., & Goodman, R. (2005). Construct and predictive validity of the repeatable battery for the assessment of neuropsychological status in the evaluation of stroke patients. Journal of Clinical and Experimental Neuropsychology, 27(1), 16-32.
35. Larson, E. B., Kirschner, K., Bode, R. K., Heinemann, A. W., Clorfene, J., & Goodman, R. (2003). Brief cognitive assessment and prediction of functional outcome in stroke. Topics in Stroke Rehabilitation, 9(4), 10-21.
36. Loughland, C. M., Carr, V. J., Lewin, T. J., Barnard, R. E., Chapman, J. L., & Walton, J. M. (2004). Potential sampling and recruitment source impacts in schizophrenia research. Psychiatry Research, 125(2), 117-127.
37. Loughland, C. M., Lewin, T. J., Carr, V. J., Sheedy, J., & Harris, A. W. (2007). RBANS neuropsychological profiles within schizophrenia samples recruited from non-clinical settings. Schizophrenia Research, 89(1-3), 232-242.
38. Maeda, K., Kasai, K., Watanabe, A., Henomatsu, K., Rogers, M. A., & Kato, N. (2006). Effect of subjective reasoning and neurocognition on medication adherence for persons with schizophrenia. Psychiatric Services, 57(8), 1203-1205.
39. McGurk, S. R., Lee, M. A., Jayathilake, K., & Meltzer, H. Y. (2004). Cognitive effects of olanzapine treatment in schizophrenia. MedGenMed: Medscape General Medicine, 6(2), 27.
40. Milev, P., Ho, B. C., Arndt, S., & Andreasen, N. C. (2005). Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up. American Journal of Psychiatry, 162(3), 495-506.
41. Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., Goldberg, T., Heaton, R. K., Keefe, R. S., Kraemer, H., Mesholam-Gately, R., Seidman, L. J., Stover, E., Weinberger, D. R., Young, A. S., Zalcman, S., & Marder, S. R. (2008). The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity. American Journal of Psychiatry, 165(2), 203-213.
42. Patton, D. E., Duff, K., Schoenberg, M. R., Mold, J., Scott, J. G., & Adams, R. L. (2003). Performance of cognitively normal African Americans on the RBANS in community dwelling older adults. The Clinical Neuropsychologist, 17(4), 515-530.
43. Patton, D. E., Duff, K., Schoenberg, M. R., Mold, J., Scott, J. G., & Adams, R. L. (2005). Base rates of longitudinal RBANS discrepancies at one- and two-year intervals in community-dwelling older adults. The Clinical Neuropsychologist, 19(1), 27-44.
44. Patton, D. E., Duff, K., Schoenberg, M. R., Mold, J., Scott, J. G., & Adams, R. L. (2006). RBANS index discrepancies: base rates for older adults. Archives of Clinical Neuropsychology, 21(2), 151-160.
45. Randolph, C. (1998). Repeatable battery for the assessment of neuropsychological status manual. San Antonio, TX: The Psychological Corporation.
46. Revheim, N., Schechter, I., Kim, D., Silipo, G., Allingham, B., Butler, P., & Javitt, D. (2006). Neurocognitive and symptom correlates of daily problem-solving skills in schizophrenia. Schizophrenia Research, 83(2-3), 237-245.
47. Rhinewine, J. P., Lencz, T., Thaden, E. P., Cervellione, K. L., Burdick, K. E., Henderson, I., Bhaskar, S., Keehlisen, L., Kane, J., Kohn, N., Fisch, G. S., Bilder, R. M., & Kumara, S. (2005). Neurocognitive profile in adolescents with early-onset schizophrenia: clinical correlates. Biological Psychiatry, 58(9), 705-712.
48. Rosenheck, R., Leslie, D., Keefe, R., McEvoy, J., Swartz, M., Perkins, D., Stroup, S., Hsiao, J. K., & Lieberman, J. (2006). Barriers to employment for people with schizophrenia. American Journal of Psychiatry, 163(3), 411-417.
49. Stip, E., Sepehry, A. A., Prouteau, A., Briand, C., Nicole, L., & Lalonde, P., & Lesage, A. (2005). Cognitive discernible factors between schizophrenia and schizoaffective disorder. Brain and Cognition, 59(3), 292-295.
50. Velligan, D. I., & Miller, A. L. (1999). Cognitive dysfunction in schizophrenia and its importance to outcome: The place of atypical antipsychotics in treatment. Journal of Clinical Psychiatry, 60(Suppl 23), 25-28.
51. Weber, B. (2003). RBANS has reasonable test-retest reliability in schizophrenia. Evidence Based Mental Health, 6(1), 22.
52. Wilk, C. M., Gold, J. M., Bartko, J. J., Dickerson, F., Fenton, W. S., Knable, M., Randolph, C., & Buchanan, R. W. (2002). Test-retest stability of the repeatable battery for the assessment of neuropsychological status in schizophrenia. American Journal of Psychiatry, 159(5), 838-844.
53. Wilk, C. M., Gold, J. M., Humber, K., Dickerson, F., Fenton, W. S., & Buchanan, R. W. (2004). Brief cognitive assessment in schizophrenia: Normative data for the Repeatable Battery for the Assessment of Neuropsychological status. Schizophrenia Research, 70(2-3), 175-186.